Safety of megadose meropenem in the empirical treatment of nosocomial sepsis: a pilot randomized clinical trial - supplementary table

Objective: To evaluate the safety of megadose meropenem as empirical treatment of nosocomial sepsis.

Materials & methods: Critically ill patients diagnosed with sepsis received either high-dose (2 g every 8 h)

or megadose (4 g every 8 h) meropenem as an intravenous infusion over 3 h. Results: A total of 23 patients

with nosocomial sepsis were eligible and included in the megadose (n = 11) or high-dose (n = 12) group.

No treatment-related adverse events were observed during a 14-day follow-up. Clinical response was also

comparable between the groups. Conclusion: Megadose meropenem may be considered for empirical

treatment of nosocomial sepsis without serious concern regarding its safety.